FILE COPY

## Notice of References Cited

Application/Control No.

O9/504,280

Examiner

David S Romeo

Applicant(s)/Patent Under
Reexamination
CLARK, MIKE A.

Art Unit
Page 1 of 1

## **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	А	US-		-	
	В	US-	- "		
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

## **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	EP 0 401 384	12-1990	Europe	Ishikawa et al.	
	0					
	Р					
	Q					
	R					
	s					
	Т					

## **NON-PATENT DOCUMENTS**

<del></del>	NON-I ALENT DOCUMENTO				
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)			
	U	Tsutsumi et al. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. Br J Cancer. 1996 Oct;74(7):1090-5.			
	٧	Mark et al. Site-specific mutagenesis to modify the human tumor necrosis factor gene. Methods Enzymol. 1987;154:403-14.			
	w	Tsutsumi et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br J Cancer. 1995 May;71(5):963-8.			
	x	Satake-Ishikawa et al. Chemical modification of recombinant human granulocyte colony-stimulating factor by polyethylene glycol increases its biological activity in vivo. Cell Struct Funct. 1992 Jun;17(3):157-60.			

<sup>\*</sup>A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.